TABLE 1.
Baseline Clinical and Demographic Characteristics and Virologic Outcomes of Participants With Preexisting INSTI-R
| Participant ID | Study*/Status | Age, y | Sex | Race | HIV Subtype | CD4 Count | Viral Load, Copies/mL | |
| Baseline | Week 48 LOCF | |||||||
| 1 | 1489/Naive | 58 | M | Black | B | 722 | 30,000 | <20 |
| 2 | 1878/VS | 44 | M | White | B | 187 | No HIV-1 RNA | No HIV-1 RNA |
| 3 | 4580/VS | 71 | M | Black | B | 464 | No HIV-1 RNA | <20 |
| 4 | 4580/VS | 37 | M | Black | B | 701 | No HIV-1 RNA | No HIV-1 RNA |
| 5 | 4580/VS | 52 | M | Other | B | 74 | No HIV-1 RNA | <20 |
| 6 | 4580/VS | 48 | M | Black | B | 777 | No HIV-1 RNA | No HIV-1 RNA |
| 7 | 1844/VS | 59 | M | White | B | 941 | No HIV-1 RNA | No HIV-1 RNA |
| 8 | 4580/VS | 63 | F | Black | B | 895 | No HIV-1 RNA | No HIV-1 RNA |
| 9 | 4030/VS | 51 | M | White | B | 507 | No HIV-1 RNA | No HIV-1 RNA |
| 10 | 4030/VS | 35 | M | White | B | 722 | <20 | No HIV-1 RNA |
| 11 | 1878/VS | 20 | M | Black | B | 552 | <20 | <20 |
| 12 | 4030/VS | 59 | M | White | B | 641 | No HIV-1 RNA | No HIV-1 RNA† |
| 13 | 1844/VS | 41 | F | Black | AG | 124 | <20 | <20 |
| 14 | 4580/VS | 60 | F | Black | B | 1394 | <20 | No HIV-1 RNA |
| 15 | 4030/VS | 64 | M | Black | B | 547 | <20 | <20 |
| 16 | 4580/VS | 44 | M | Black | B | 465 | <20 | No HIV-1 RNA |
| 17 | 4580/VS | 57 | F | Black | B | 921 | No HIV-1 RNA | No HIV-1 RNA |
| 18 | 4030/VS | 31 | M | White | B | 820 | No HIV-1 RNA | No HIV-1 RNA |
| 19 | 4030/VS | 48 | M | Black | C | 188 | No HIV-1 RNA | No HIV-1 RNA |
| 20 | 4030/VS | 53 | F | Black | C | 588 | No HIV-1 RNA | No HIV-1 RNA |
*
Participants were required to have been suppressed for a minimum of 3–6 months depending on the study.
†
Participant 12 had viral load measurements until week 12 when they decided to withdraw.